---
title: "Safety Study of AMG 228 to Treat Solid Tumors"
description: "The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity, and identify a tolerable dose of AMG 228 in subjects with advan"
url: "https://www.clareohealth.com/clinical-trials/NCT02437916"
---

The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity, and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.

## Key Facts

**ID:** NCT02437916
**Status:** TERMINATED
**Phase:** PHASE1
**Type:** INTERVENTIONAL
**Enrollment:** 30
**Sponsor:** Amgen

## Conditions

- Advanced Malignancy
- Advanced Solid Tumors
- Cancer
- Oncology
- Oncology Patients
- Tumors
- Melanoma
- Non-small Cell Lung Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Transitional Cell Carinoma of Bladder
- Colorectal Cancer

## Interventions

**DRUG: AMG 228**
AMG 228 will be administered intravenously

## Eligibility

Inclusion Criteria: * Subject must have a pathologically documented, definitively diagnosed, advanced solid tumor * Adequate hematological, renal, hepatic, and coagulation laborat…

## Who Can Participate

**Minimum age:** 18

**Sex:** ALL

**Accepts healthy volunteers:** No

## Study Locations

- Research Site, La Jolla, California, United States
- Research Site, New Haven, Connecticut, United States
- Research Site, New York, New York, United States
- Research Site, Parkville, Victoria, Australia
- Research Site, Leuven, Belgium
- Research Site, Villejuif, France
- Research Site, Heidelberg, Germany

## Contact Information

## Important Dates

**Study start:** April 21, 2015

**Completion date:** December 12, 2016

**Last updated:** November 8, 2022

[View on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02437916)
